Skip to main content
. Author manuscript; available in PMC: 2021 Sep 1.
Published in final edited form as: Anticancer Drugs. 2020 Sep;31(8):759–775. doi: 10.1097/CAD.0000000000000962

Figure 7. GSK346294A suppresses stem cell-like behavior of TNBC cells.

Figure 7.

Pre-treated MDA-MB-231 M2 mammospheres (DMSO, GSK346294A (1μM)) were injected bilaterally into the mfp of SCID/Beige mice at different numbers of cell concentrations (200,000 cells, 100,000 cells, 50,000 cells, 10,000 cells, 1,000 cells). Notably, in the DMSO treatment group, the mouse injected with 200,000 cells/tumor died three days after injections. Tumorigenesis data of the pre-treated (A) DMSO and (B) GSK346294A groups are shown. Pre-treated TU-BcX-4IC M2 mammospheres (DMSO, GSK346294A (1μM)) were injected bilaterally into the mfp of SCID/Beige mice (100,000 cells/injection; n = 5 mice/group). (C, D) Tumorigenesis data of the pre-treated DMSO and GSK346294A groups are shown. Tumor areas were measured biweekly with calipers. Tumors were resected and after 20 additional days mice were sacrificed. Lungs and livers were harvested, formalin fixed, paraffin-embedded and H & E stained to visualize metastasis. Metastatic lesions were measured and quantified using the AperioImage program.